This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
In short, recently a study looked at two groups of a total 120 genotype 1b patients who treated with triple therapy: Telaprevir added to pegylated interferon-α2b and ribavirin. Group A consisted of 64 patients older then 60 years of age and group B, 56 patients less then 60. The study found no significant difference in (cure) sustained virological response(SVR) between groups A (76.6%) and B (83.9%), researchers concluded triple therapy can be used successfully to treat older patients with genotype 1b chronic hepatitis C. Click below to view the abstract in more detail,, the full text requires payment HCV in elderly patients"
The link provided below is a great forum to connect with other people treating the virus. The discussion includes a gentlemen who was 65 when he started therapy, the message was posted in 2012, but still may be helpful. Message Boards "Med Help"
The data regarding cirrhotic patients treated with oral regimens(interferon free)(not FDA approved) comes from the SOUND-C2 study, where a NS3 protease inhibitor (faldaprevir), a non nucleoside NS5B inhibitor (BI207127) and ribavirin were combined in genotype 1 naïve patients: reported SVR12 rates in cirrhotics were around 60%(17). The article can be found here Although you didn't mention your genotype these links will give you a start, as always talking to your doctor is the best avenue to explore. Again, good luck
I have Hep C from a blood transfusion in the early seventies and have progressed to early cirrhosis. Is there still hope for me. I am 65 years old.
ReplyDeleteIn short, recently a study looked at two groups of a total 120 genotype 1b patients who treated with triple therapy: Telaprevir added to pegylated interferon-α2b and ribavirin. Group A consisted of 64 patients older then 60 years of age and group B, 56 patients less then 60. The study found no significant difference in (cure) sustained virological response(SVR) between groups A (76.6%) and B (83.9%), researchers concluded triple therapy can be used successfully to treat older patients with genotype 1b chronic hepatitis C. Click below to view the abstract in more detail,, the full text requires payment
ReplyDeleteHCV in elderly patients"
The link provided below is a great forum to connect with other people treating the virus. The discussion includes a gentlemen who was 65 when he started therapy, the message was posted in 2012, but still may be helpful.
Message Boards "Med Help"
Wishing you the best my friend
Tina
The data regarding cirrhotic patients treated with oral regimens(interferon free)(not FDA approved) comes from the SOUND-C2 study, where a NS3 protease inhibitor (faldaprevir), a non nucleoside NS5B inhibitor (BI207127) and ribavirin were combined in genotype 1 naïve patients: reported SVR12 rates in cirrhotics were around 60%(17).
ReplyDeleteThe article can be found here Although you didn't mention your genotype these links will give you a start, as always talking to your doctor is the best avenue to explore.
Again, good luck